Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Adaptive immune responses elicited by T and B cells are crucial for the control of viral infections. Antigen presenting cells (APC) such as dendritic cells (DC) process incoming antigens and present them to CD4+ or CD8+ T cells, inducing their activation, clonal selection, and subsequent proliferation. During viral infection, restricting viral replication and spread is essential to host survival and to limit disease severity. T cells have been indicated to be indispensable for limiting viral replication. During this process, CD4+ T helper T cell populations (Th) which support the generation of antibody producing B cells and secrete pro-inflammatory cytokines, such as interferon gamma (IFNγ), promoting clearance of the infection, increase. In parallel, a pool of heterogenous antigen-specific long-lasting memory CD4+ and CD8+ T cells is generated. Among those CD4+ and CD8+ memory T cells, effector memory re-expressing CD45RA (TEMRA) T cells have recently been identified to be major contributors to tissue-resident immunity to viruses, in particular SARS-CoV-2. Within the tissue, TEMRA cells provide a rapidly activated, antigen-specific, long-lasting first barrier to reinfection and induction of TEMRA cells by vaccination often correlates with enhanced protection.

During early infection, SARS-CoV-2 induces antigen-specific CD4+ and CD8+ T cells, which exhibit a prototypical antiviral phenotype (i.e., IFNγ+, IL-2+) and are detectable even during convalescence. Several studies have reported a positive correlation between the magnitude and timing of T cell responses with antibody production and disease severity. Recently, it was discovered that in spite of the high specificity of T cell responses conferred by the T cell receptor (TCR), cross-reactive memory T cells can be found in humans and in experimental mouse models and were shown to exhibit reactivity to different influenza A virus strains in naive donors or to induce cross-protection to Zika Virus in patients seropositive for Dengue virus, a phenomenon termed heterologous immunity. Similarly, T cells reactive to SARS-CoV-2 peptides have been isolated from patients who were infected with SARS-CoV more than 10 years ago or from healthy donors exposed to other coronaviruses causing the common cold.

Vaccines, such as BCG, the measles-mumps-rubella (MMR) and tetanus-diphtheria-pertussis (Tdap) have been shown to induce adaptive heterologous immunity, but the biological significance of such heterologous immunity remains unclear although it could potentially inform the design of more efficient vaccines (Figure 1). To shed further light on the molecular processes underlying heterologous adaptive immunity in response to SARS-CoV-2, Mysore and colleagues developed a refined approach to study antigen-specific T cell responses and reported the identification of a heterologous T cell pool sharing responsiveness to SARS-CoV-2 and the antigens of two of the most used vaccines in humans, MMR and Tdap. In this study the authors use highly activated SARS-CoV-2 or MMR/Tdap vaccine antigen pulsed neutrophils or monocyte-derived DCs from the blood of SARS-CoV-2 infected patients or healthy donors, to allow physiological antigen processing, and subsequently co-culture those APCs with autologous T cells to evaluate T cell reactivity.

Interestingly the authors not only observed strong memory T cell activation specific to nucleocapsid and the S1 spike protein of SARS-CoV-2, but also reactivation of memory T cells toward antigen contained within the MMR and Tdap vaccines. These recall responses were higher in infected individuals than in healthy ones and in contrast to IgG antibodies, they were readily detected early during infection. An increase of memory T cells reactive to the S1 spike but also to MMR and Tdap antigens was observed in samples from individuals who received the Moderna mRNA-1273 COVID-19 vaccine 2.5 months after the second dose, confirming cross-reactivity to other antigens induced by vaccination.

1 Quantitative Systems Biology, Life and Medical Sciences (LIMES) Institute, University of Bonn, Germany
2 Correspondence: andreas.schlitzer@uni-bonn.de
3 https://doi.org/10.1016/j.medj.2021.08.009
Phenotypic characterization of the heterologous reactive T cells revealed a prevalent and overlapping population of CD4+ TEMRA expressing IFNγ+, GPR56+, and CX3CR1+, providing them with the molecular toolbox to enter peripheral tissues and to provide adaptive first line defense. CD8+ TEMRA were also reactive to all antigens, although they were lower in COVID-19-vaccinated individuals than in convalescent ones. To reveal the underlying molecular mechanisms of heterologous immunity in the identified TEMRA populations, single-cell mRNA sequencing together with TCR sequencing was performed and identified more than 10,000 TCR clonotypes. Among those 10,000 clonotypes, 90 heterologous clonotypes were found, of which 30 were shared across all assessed donors. The authors also confirmed their identity as cytotoxic TEMRA cells according to their transcriptomic profile.

To extend these findings and assess if heterologous immunity to SARS-CoV-2, MMR, and Tdap antigens contributed to the breadth of severity seen during SARS-CoV-2 infection, the authors retrospectively investigated a cohort of 11,483 and 36,793 infected patients previously vaccinated with MMR or Tdap, respectively. After adjusting for several demographic traits and risk factors, the authors observed a 38% or 23% decrease of COVID-19 severity in individuals who were previously immunized against MMR or Tdap, respectively. This suggests that previous events, such as vaccination or infection, enhance the immune response to SARS-CoV-2.

Although previous ex vivo studies had shown that pre-existent memory T cells exist and recognize antigenic peptides related to SARS-CoV-2,⁵,⁷ the existence of heterologous T cell clones recognizing physiologically processed antigen remained elusive. Here, the authors combined physiological processing of SARS-CoV-2 with a single-cell resolution characterization of TCR specificity and diversity, generating a detailed helpful resource to understand the transcriptional basis of heterologous T cell responses and to utilize such knowledge designing more efficient vaccines.¹

Convalescent and COVID-19 mRNA vaccinated individuals exhibited a significant increase of MMR- and Tdap-specific TEMRA cells corroborating the efficacy of vaccines in triggering a heterologous adaptive response to SARS-CoV-2.¹ CD8+ TEMRA cells have been shown to be essential for viral control and as a central cornerstone for the control of reinfection. Intriguingly, a subtle difference between SARS-CoV-2 and vaccination with COVID-19 mRNA vaccines was described. Here, vaccines were shown to exhibit a lower amount of activated CD8+ TEMRA cells post vaccination. Therefore, studies comparing the effect of vector-based and mRNA vaccines regarding induction of heterologous CD8+ TEMRA are necessary to evaluate novel vaccination designs and schemes.

Viral- and bacterial-derived antigens have been shown to induce heterologous adaptive immunity, converging on a similar repertoire of memory T cells that...
are cross-reactive to SARS-CoV-2 peptides. Additionally, BCG, the world’s most used vaccine, confers some protection toward infection with Yellow Fever Virus (YFV) and other types of pathogens in vivo. Recently, YFV itself has been linked with the induction of heterologous innate immunity, also termed trained immunity, in humans. Both induction of trained immunity by BCG and YFV have been linked to a reprogramming of myeloid cell progenitors and effector cells, inducing a marked metabolic and secretory switch, enhancing the amplitude and duration of inflammatory responses, allowing for an increased first line defense against invading pathogens. Mechanisms of the induction of adaptive heterologous immune responses remain elusive, except for the notion that shared TCR specificities are triggered by antigenic similarity. However, the mechanisms by which TEMRA cells are preferentially generated, and there is a strict licensing dependency toward interleukin 15, remain unknown. Further studies elucidating the transcriptional networks active in heterologous T cells are urgently needed (Figure 1).

The clinical benefits of BCG-induced trained immunity are currently evaluated in first-line health care workers in regards to protection and severity of COVID-19 (NCT04659941, NCT04648800, NCT04384549, NCT04348370). Here the effect of MMR and Tdap vaccination was retrospectively evaluated and a reduction of severe COVID-19 was found and attributed to the induction of heterologous adaptive immune response. However, effects of the innate immune system cannot be ruled out in this retrospective analysis as MMR and Tdap have been shown before to induce trained immunity in humans.

Collectively, robust, specific, and long-lasting T cell responses are essential to protect against viral infection, especially in the absence of efficient antibody responses as it occurs in elderly. Here, the authors highlight that heterologous adaptive immunity, inducing efficient TEMRA effector cells, might prove a novel avenue to increase overall immunity against viruses and other pathogens. Therefore, these data build a foundation to incorporate the benefits of heterologous adaptive and innate immunity into the design and development of novel vaccine toolboxes and vaccination schemes to counteract the current ongoing SARS-CoV-2 pandemic and to increase preparedness toward new and as of now unknown pathogens with pandemic potential (Figure 1).

ACKNOWLEDGMENTS

This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—EXC 2151–390873048 and an Emmy Noether fellowship to A.S. (SCHL2116/1-1). D.A.B. is supported by an Arge-lander fellowship of the University of Bonn.

DECLARATION OF INTERESTS

The authors declare no competing interests.

1. Mysore, V., Cullere, X., Settles, M.L., Ji, X., Kattan, M.W., Desjardins, M., Durbin-Johnson, B., Gilboa, T., Baden, L.R., Walt, D.R., et al. (2021). Protective heterologous T cell immunity in COVID-19 induced by the trivalent Measles-Mumps-Rubella and Tetanus-Diphtheria-Pertussis vaccine antigens. Med 2, 1050–1071. https://doi.org/10.1016/j.medj.2021.08.004.

2. Rosendahl Huber, S., van Beek, J., de Jonge, J., Luytjes, W., and van Baarle, D. (2014). T cell responses to viral infections - opportunities for Peptide vaccination. Front. Immunol. 5, 171. https://doi.org/10.3389/fimmu.2014.00171.

3. Neidlerman, J., Luo, X., Frouard, J., Xie, G., Gill, G., Stein, E.S., McGregor, M., Ma, T., George, A.F., Karpers, A., et al. (2020). SARS-CoV-2 Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep. Med. 1, 100081. https://doi.org/10.1016/j.xcrm.2020.100081.

4. Ryczynski Moberbach, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hasenie, K.M., Weiskopf, D., Belanger, S., Abbott, R.K., Kim, C., Chao, J., et al. (2020). Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and DiseaseSeverity. Cell 183, 996–1012.e19. https://doi.org/10.1016/j.cell.2020.09.038.

5. Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chong, M.H.Y., Lin, M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457–462. https://doi.org/10.1038/s41586-020-2550-z.

6. Messina, N.L., Zimmermann, P., and Curtis, N. (2019). The impact of vaccines on heterologous adaptive immunity. Clin. Microbiol. Infect. 25, 1484–1493. https://doi.org/10.1016/j.cmi.2019.02.016.

7. Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moberbach, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 181, 1489–1501.e15. https://doi.org/10.1016/j.cell.2020.05.015.

8. Arts, R.J.W., Mooilag, S.J.C.F.M., Novakovic, B., Li, Y., Wang, S.-Y., Oosting, M., Kumar, V., Xavier, R.J., Wijmenga, C., Joosten, L.A.B., et al. (2018). BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe 23, 89–100.e5. https://doi.org/10.1016/j.chom.2017.12.010.

9. Cirovic, B., de Bree, L.C.J., Groh, L., Blok, B.A., Chan, J., van der Velden, W.J.F.M., Bremmers, M.E.J., van Crevel, R., Händler, K., Picelli, S., et al. (2020). BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. Cell Host Microbe 28, 322–334.e5. https://doi.org/10.1016/j.chom.2020.05.014.

10. O’Neill, L.A.J., and Netea, M.G. (2020). BCG-induced trained immunity: can it offer protection against COVID-19? Nat. Rev. Immunol. 20, 335–337. https://doi.org/10.1038/s41575-020-0337-y.